Acelyrin (SLRN) Expected to Announce Quarterly Earnings on Thursday

Acelyrin (NASDAQ:SLRN) is expected to post its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect Acelyrin to post earnings of ($0.84) per share for the quarter.

Acelyrin (NASDAQ:SLRN) last released its earnings results on Wednesday, March 19th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.07. On average, analysts expect Acelyrin to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Acelyrin Trading Down 4.9 %

SLRN stock opened at $2.51 on Wednesday. The stock has a market capitalization of $252.78 million, a P/E ratio of -1.02 and a beta of 1.27. The firm has a 50-day moving average price of $2.31 and a 200-day moving average price of $3.78. Acelyrin has a 12 month low of $1.85 and a 12 month high of $7.25.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on SLRN shares. Citigroup decreased their target price on shares of Acelyrin from $6.00 to $3.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 7th. HC Wainwright reduced their price objective on Acelyrin from $8.00 to $6.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 7th. Finally, Wells Fargo & Company lowered their target price on Acelyrin from $15.00 to $13.00 and set an “overweight” rating for the company in a report on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $9.60.

Insider Activity

In other news, CEO Mina Kim sold 17,986 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $2.74, for a total value of $49,281.64. Following the completion of the sale, the chief executive officer now owns 671,753 shares of the company’s stock, valued at approximately $1,840,603.22. This represents a 2.61 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 13.60% of the company’s stock.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.